Your browser doesn't support javascript.
loading
Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution.
Kosugi, Yusuke; Plianchaisuk, Arnon; Putri, Olivia; Uriu, Keiya; Kaku, Yu; Hinay, Alfredo A; Chen, Luo; Kuramochi, Jin; Sadamasu, Kenji; Yoshimura, Kazuhisa; Asakura, Hiroyuki; Nagashima, Mami; Ito, Jumpei; Sato, Kei.
Afiliação
  • Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Plianchaisuk A; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Putri O; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Biomedicine, School of Life Sciences, Indonesia International Institute for Life Sciences (i3L), Jakarta, Indonesia.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kaku Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hinay AA; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Chen L; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
  • Kuramochi J; Interpark Kuramochi Clinic, Utsunomiya, Japan; Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.
  • Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Scienc
Lancet Microbe ; 5(4): e313, 2024 04.
Article em En | MEDLINE | ID: mdl-38219759
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Lancet Microbe Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Lancet Microbe Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido